» Articles » PMID: 36387381

Mutation of FMDV L H138 Residue Drives Viral Attenuation in Cell Culture and in Swine

Abstract

The foot-and-mouth disease virus (FMDV) leader proteinase (L) is a papain like protease that cleaves the viral polyprotein and several host factors affecting host cell translation and induction of innate immunity. Introduction of L mutations ablating catalytic activity is not tolerated by the virus, however, complete coding sequence deletion or introduction of targeted amino acid substitutions can render viable progeny. In proof-of-concept studies, we have previously identified and characterized FMDV L mutants that are attenuated in cell culture and in animals, while retaining their capacity for inducing a strong adaptive immunity. By using molecular modeling, we have now identified a His residue (H138), that resides outside the substrate binding and catalytic domain, and is highly conserved across serotypes. Mutation of H138 renders possible FMDV variants of reduced virulence and . Kinetics studies showed that FMDV A12-L mutant replicates similarly to FMDV A12-wild type (WT) virus in cells that do not offer immune selective pressure, but attenuation is observed upon infection of primary or low passage porcine epithelial cells. Western blot analysis on protein extracts from these cells, revealed that while processing of translation initiation factor eIF-4G was slightly delayed, no degradation of innate sensors or effector molecules such as NF-κB or G3BP2 was observed, and higher levels of interferon (IFN) and IFN-stimulated genes (ISGs) were induced after infection with A12-L as compared to WT FMDV. Consistent with the results in porcine cells, inoculation of swine with this mutant resulted in a mild, or in some cases, no clinical disease but induction of a strong serological adaptive immune response. These results further support previous evidence that L is a reliable target to derive numerous viable FMDV strains that alone or in combination could be exploited for the development of novel FMD vaccine platforms.

Citing Articles

The Strategies Used by Animal Viruses to Antagonize Host Antiviral Innate Immunity: New Clues for Developing Live Attenuated Vaccines (LAVs).

Chen N, Zhang B Vaccines (Basel). 2025; 13(1).

PMID: 39852825 PMC: 11768843. DOI: 10.3390/vaccines13010046.


Virulence and Immune Evasion Strategies of FMDV: Implications for Vaccine Design.

Medina G, Diaz San Segundo F Vaccines (Basel). 2024; 12(9).

PMID: 39340101 PMC: 11436118. DOI: 10.3390/vaccines12091071.


A review of foot-and-mouth disease in Ethiopia: epidemiological aspects, economic implications, and control strategies.

Zewdie G, Akalu M, Tolossa W, Belay H, Deresse G, Zekarias M Virol J. 2023; 20(1):299.

PMID: 38102688 PMC: 10724896. DOI: 10.1186/s12985-023-02263-0.


Reprogramming viral immune evasion for a rational design of next-generation vaccines for RNA viruses.

Su C, Du Y, Rowland R, Wang Q, Yoo D Front Immunol. 2023; 14:1172000.

PMID: 37138878 PMC: 10149994. DOI: 10.3389/fimmu.2023.1172000.

References
1.
Knowles N, Samuel A . Molecular epidemiology of foot-and-mouth disease virus. Virus Res. 2003; 91(1):65-80. DOI: 10.1016/s0168-1702(02)00260-5. View

2.
Kumari P, Kumar H . Viral deubiquitinases: role in evasion of anti-viral innate immunity. Crit Rev Microbiol. 2017; 44(3):304-317. DOI: 10.1080/1040841X.2017.1368999. View

3.
Mayer C, Neubauer D, Nchinda A, Cencic R, Trompf K, Skern T . Residue L143 of the foot-and-mouth disease virus leader proteinase is a determinant of cleavage specificity. J Virol. 2008; 82(9):4656-9. PMC: 2293068. DOI: 10.1128/JVI.02077-07. View

4.
De Los Santos T, Diaz-San Segundo F, Rodriguez L . The need for improved vaccines against foot-and-mouth disease. Curr Opin Virol. 2018; 29:16-25. DOI: 10.1016/j.coviro.2018.02.005. View

5.
Carrillo C, Tulman E, Delhon G, Lu Z, Carreno A, Vagnozzi A . Comparative genomics of foot-and-mouth disease virus. J Virol. 2005; 79(10):6487-504. PMC: 1091679. DOI: 10.1128/JVI.79.10.6487-6504.2005. View